|
Ambrilia Biopharma Conference Call October 12, 2006 9:30 AM ET |
|||||
|
|||||
|
About the company Ambrilia Biopharma Inc. (TSX:AMB) is a biopharmaceutical company developing innovative therapeutics in the fields of oncology and infectious diseases. Ambrilia's product portfolio includes mid to early-stage products and two specialty generics, the first of which is late-stage and value-added. Ambrilia's first generic product is Octreotide, an easily reconstituted LAR equivalent to Novartis's Sandostatin®, used for the treatment of a rare disease called acromegaly caused by a tumor of the pituitary gland, and for certain rare digestive tumors. The second product is Goserelin, a potential first-to-market generic alternative to Astra Zeneca's Zoladex®, used primarily for the treatment of hormone-sensitive prostate cancer. Ambrilia's mid to early-stage products include: PPL-100, a promising protease inhibitor for the treatment of HIV/AIDS currently in Phase I clinical trials; PCK3145, a therapeutic anti-cancer peptide with signal transduction mediated effects on tumor metastasis and angiogenesis soon to enter a Phase II North American trial for prostate cancer; TVT-Dox, a novel anti-cancer technology targeting tumor vasculature for which an IND filing for the treatment of solid tumors is expected in 2008; SPC3, a fusion inhibitor for the treatment of HIV/AIDS which is at the preclinical stage and an integrase inhibitor program for the treatment of HIV/AIDS. Ambrilia's diagnostic products include PSP94 (Prostate Secretory Protein of 94 amino acids) immunoassay for the diagnosis and prognosis of prostate cancer. Ambrilia's head office, Research and Development and Manufacturing facilities are located in Montreal with a regional office in France. |
|||||
Visit our web site at
www.ambrilia.com.
|
|||||